KNSA - Kiniksa Pharmaceuticals GAAP EPS of $0.21 beats by $0.38 revenue of $71.47M beats by $19.27M

2023-07-25 07:36:11 ET

• Kiniksa Pharmaceuticals press release ( NASDAQ: KNSA ): Q2 GAAP EPS of $0.21 beats by $0.38 .
• Revenue of $71.47M (+165.0% Y/Y) beats by $19.27M .
• Total revenue for the second quarter of 2023 included $54.5 million in ARCALYST net product revenue and $17.0 million in license and collaboration revenue, compared to $27.0 million in ARCALYST net product revenue and $0.0 million in license and collaboration revenue for the second quarter of 2022.

• Financial Guidance

  • Kiniksa now expects 2023 ARCALYST net product revenue of between $220 million and $230 million compared to prior guidance of between $200 million and $215 million.
  • Kiniksa now expects that its cash and cash equivalents will fund its current operating plan into at least 2027.

For further details see: